chenodeoxycholic acid has been researched along with propyl gallate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Balic, K; Grimsby, J; Huang, Y; Konkar, A; Liang, L; Naylor, J; Patel, C; Pechenov, S; Revell, J; Rosenbaum, AI; Subramony, JA; Tseng, L; Tyagi, P; Will, S | 1 |
1 review(s) available for chenodeoxycholic acid and propyl gallate
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
1 other study(ies) available for chenodeoxycholic acid and propyl gallate
| Article | Year |
|---|---|
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Topics: Administration, Oral; Animals; Caco-2 Cells; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; CHO Cells; Chronic Disease; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Drug Delivery Systems; Drug Discovery; Glucagon-Like Peptide-1 Receptor; Humans; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Peptides; Propyl Gallate; Protein Engineering; Receptors, Glucagon; Tablets, Enteric-Coated | 2021 |